Translating Stanford discoveries into individualized cancer care
Every day, people living with cancer come to Stanford for help, hope and healing.
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still.
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Colorectal cancers often spread before the initial tumor is detected, according to a new Stanford study. Identifying patients in whom early metastasis is likely could better guide treatment decisions.
E-cigarette flavorings damage human blood vessel cells grown in the lab even in the absence of nicotine, Stanford researchers and their colleagues found. Cinnamon and menthol flavors were particularly harmful.
In 2012, a pair of neurosurgery residents traded their scrubs for lab coats in an effort to understand, at the most basic level, what causes medulloblastoma, the most common pediatric brain cancer.
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.
